Advertisement

Topics

Swissmedic Company Profile

14:26 EST 16th December 2018 | BioPortfolio

Swissmedic, the Swiss Agency for Therapeutic Products, is a public institution of the Swiss government. It is affiliated to the Federal Department of Home Affairs. The legal basis of Swissmedic is the Swiss Federal Law on Medicinal Products and Medical De

Location

Hallerstrasse 7,Postfach
Bern 9
3000
Switzerland

Contact

Phone: 41 (0)31 322 02 11
Fax: 41 (0)31 322 02 12
Email: Beatrice.Jobaro@swissmedic.ch


News Articles [8 Associated News Articles listed on BioPortfolio]

Novartis erhält von Swissmedic Zulassung für Aimovig zur Migräneprävention

Das Schweizerische Heilmittelinstitut Swissmedic habe das Präparat zur Migräneprävention von Novartis zugelassen, sofern diese indiziert ist, heisst es in einer entsprechenden Medienmitteilung vom ...

Swissmedic Cracks Down On Marketing Applications With Missing Data

Applications for marketing authorization or variations in Switzerland might have to repeat the first phase of Swissmedic’s evaluation process if...    

Swissmedic approves fibryga to treat congenital and acquired fibrinogen deficiencies

This approval is an important achievement for the company and most importantly, represents major progress for patients and physicians. Octapharma board member Olaf Walter said: “The development of ...

DGAP-News: Biofrontera AG: Swissmedic erteilt die Zulassung für Ameluz(R) in Kombination mit photodynamischer Tageslichttherapie in der Schweiz (deutsch)

Biofrontera AG: Swissmedic erteilt die Zulassung für Ameluz(R) in Kombination mit photodynamischer Tageslichttherapie in der Schweiz DGAP-News: Biofrontera AG / Schlagwort(e): Sonstiges Biofronter...

Biofrontera: Schweizer Genehmigung

In der Schweiz erhält Biofrontera die Zulassungserweiterung für Ameluz in Kombination mit einer Tageslichttherapie. Swissmedic, die entsprechende Behörde gibt dafür grünes Licht. Im März hatte s...

Biofrontera: Schweizerische Zulassung von Ameluz(R) mit Tageslicht-PDT

Bad Marienberg (www.anleihencheck.de) - Die Biofrontera AG (ISIN DE0006046113/ WKN 604611), ein internationales biopharmazeutisches Unternehmen, gab heute bekannt, dass die Swissmedic, die schweize...

Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies

Octapharma today announced that the Swiss Agency for Therapeutic Products, Swissmedic, granted marketing authorization to its new fibrinogen concentrate product fibryga® for the ...

Biofrontera AG: Swissmedic approves Ameluz(R) in combination with daylight photodynamic therapy in Switzerland

DGAP-News: Biofrontera AG / Key word(s): Miscellaneous 01.10.2018 / 14:06 The issuer is solely responsible for the content of this announcement. Swissmedic approves Ameluz(R) in combination...

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.

In this study we compared Swissmedic's (SMC's) regulatory marketing authorization decisions to those of the US Food and Drug Administration (FDA) and European drug regulatory authorities (EU). We inve...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis

A randomized controlled trial comparing Urtica comp. gel (Swissmedic listed medication in the category of "Anthroposophic Medication without Indication") against standard skin care, examin...

A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients.

Follicular lymphoma (FL) is an indolent yet incurable lymphoma characterized by initial responses to standard therapies, invariably followed by shorter disease free intervals. Obinutuzumab...

Companies [4 Associated Companies listed on BioPortfolio]

Swissmedic

Swissmedic, the Swiss Agency for Therapeutic Products, is a public institution of the Swiss government. It is affiliated to the Federal Department of Home Affairs. The legal basis of Swissmedic is the...

Micro-Sphere SA

Micro-Sphere SA was founded in 1998 and started its activity in 1999 in the new factory in Madonna del Piano in the same building where Micro-Macinazione SA is operating.Micro-Sphere SA has obtained t...

RohnerChem

Rohner, Inc. is the U.S. subsidiary of the Pratteln, Switzerland based custom manufacturer RohnerChem, a SwissMedic and FDA inspected cGMP facility. We specialize in rapid scale-up and large-scale pro...

Stemedica International S.A.

Founded in Epalinges, Switzerland, in 2008, Stemedica International S.A. is a global biotechnology company that develops therapeutic applications for the treatment and prevention ...

More Information about "Swissmedic" on BioPortfolio

We have published hundreds of Swissmedic news stories on BioPortfolio along with dozens of Swissmedic Clinical Trials and PubMed Articles about Swissmedic for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Swissmedic Companies in our database. You can also find out about relevant Swissmedic Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record